10x Genomics (TXG) Shares Outstanding (Weighted Average) (2018 - 2026)

10x Genomics has disclosed Shares Outstanding (Weighted Average) across 9 years of filings, most recently posting $128.3 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $128.3 million, up 4.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $128.3 million (up 4.64% YoY), and the FY2025 annual result was $124.7 million, up 3.57% from the prior year.
• Shares Outstanding (Weighted Average) came in at $128.3 million for Q1 2026 at 10x Genomics, up from $124.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $128.3 million in Q1 2026 to a low of $113.0 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $119.4 million (2024), against an average of $119.2 million.
• Across the five-year window, Shares Outstanding (Weighted Average) climbed 2.35% in 2023 and advanced 4.64% in 2026, its largest moves.
• 10x Genomics' Shares Outstanding (Weighted Average) stood at $113.9 million in 2022, then rose by 2.9% to $117.2 million in 2023, then grew by 2.81% to $120.5 million in 2024, then increased by 3.57% to $124.7 million in 2025, then advanced by 2.84% to $128.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $128.3 million (Q1 2026), $124.7 million (Q4 2025), and $125.5 million (Q3 2025), per Business Quant data.